Drozitumab

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.^[1][2] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.^[3][4] Drozitumab was developed by Genentech.

Drozitumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	DR5
Clinical data
ATC code	none
Identifiers
CAS Number	912628-39-8 N
ChemSpider	none
UNII	SQ67484MA7
KEGG	D09888 N
Chemical and physical data
Formula	C6334H9792N1700O2000S42
Molar mass	143104.43 g·mol−1
NY (what is this?)  (verify)

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.^[3]